SNS-103
sensei biotherapeutics
['sensei']
today at the annual meeting, sensei presented new preclinical data on the sns-103 program aimed at developing a conditionally active monoclonal antibody targeting entpdase1 (cd39): #aacr23 
Pushing the boundaries of science and imagination to discover and develop innovative medicines for patients.